BiologicalCombination product
Oncolytic Vaccinia Virus TG6002 clinical trials
Also written TG6002.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Transgene (2) · Tasly Tianjin Biopharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Oncolytic Vaccinia Virus TG6002 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerTerminatedPhase 1/2TransgeneNCT04194034Written as TG6002
- Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.TerminatedPhase 1/2TransgeneNCT03724071Written as TG6002
- Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1/2Tasly Tianjin Biopharmaceutical Co., Ltd.NCT04226066Written as T601